Biology of schizophrenia

Is treatment refractoriness synonymous with severity of illness [A.K.A. is this a drug efficacy problem or an expression of severe illness?

Helio Elkis, Peter F. Buckley

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Approximately one-quarter of individuals develop schizophrenia in early childhood and adolescence. Typically, the course of illness in these patients is deteriorative. Moreover, longitudinal evaluation of chronic relapsing illness reveals evidence of neurodegenerative tissue loss. There is some evidence-albeit preliminary and somewhat controversial-that antipsychotic medications can obviate and/or ameliorate these changes. This chapter will describe the neurobiology of schizophrenia with a focus on the timing, evolution, and putative neurobiological correlates of treatment-refractoriness in schizophrenia.

Original languageEnglish (US)
Title of host publicationTreatment-Refractory Schizophrenia
Subtitle of host publicationA Clinical Conundrum
PublisherSpringer Berlin Heidelberg
Pages21-30
Number of pages10
ISBN (Electronic)9783642452574
ISBN (Print)9783642452567
DOIs
StatePublished - Jan 1 2014

Fingerprint

Schizophrenia
Pharmaceutical Preparations
Neurobiology
Antipsychotic Agents
Chronic Disease
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Biology of schizophrenia : Is treatment refractoriness synonymous with severity of illness [A.K.A. is this a drug efficacy problem or an expression of severe illness? / Elkis, Helio; Buckley, Peter F.

Treatment-Refractory Schizophrenia: A Clinical Conundrum. Springer Berlin Heidelberg, 2014. p. 21-30.

Research output: Chapter in Book/Report/Conference proceedingChapter

Elkis, Helio ; Buckley, Peter F. / Biology of schizophrenia : Is treatment refractoriness synonymous with severity of illness [A.K.A. is this a drug efficacy problem or an expression of severe illness?. Treatment-Refractory Schizophrenia: A Clinical Conundrum. Springer Berlin Heidelberg, 2014. pp. 21-30
@inbook{33f09d6cd41c458b83a49c456748a10b,
title = "Biology of schizophrenia: Is treatment refractoriness synonymous with severity of illness [A.K.A. is this a drug efficacy problem or an expression of severe illness?",
abstract = "Approximately one-quarter of individuals develop schizophrenia in early childhood and adolescence. Typically, the course of illness in these patients is deteriorative. Moreover, longitudinal evaluation of chronic relapsing illness reveals evidence of neurodegenerative tissue loss. There is some evidence-albeit preliminary and somewhat controversial-that antipsychotic medications can obviate and/or ameliorate these changes. This chapter will describe the neurobiology of schizophrenia with a focus on the timing, evolution, and putative neurobiological correlates of treatment-refractoriness in schizophrenia.",
author = "Helio Elkis and Buckley, {Peter F.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-3-642-45257-4_2",
language = "English (US)",
isbn = "9783642452567",
pages = "21--30",
booktitle = "Treatment-Refractory Schizophrenia",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Biology of schizophrenia

T2 - Is treatment refractoriness synonymous with severity of illness [A.K.A. is this a drug efficacy problem or an expression of severe illness?

AU - Elkis, Helio

AU - Buckley, Peter F.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Approximately one-quarter of individuals develop schizophrenia in early childhood and adolescence. Typically, the course of illness in these patients is deteriorative. Moreover, longitudinal evaluation of chronic relapsing illness reveals evidence of neurodegenerative tissue loss. There is some evidence-albeit preliminary and somewhat controversial-that antipsychotic medications can obviate and/or ameliorate these changes. This chapter will describe the neurobiology of schizophrenia with a focus on the timing, evolution, and putative neurobiological correlates of treatment-refractoriness in schizophrenia.

AB - Approximately one-quarter of individuals develop schizophrenia in early childhood and adolescence. Typically, the course of illness in these patients is deteriorative. Moreover, longitudinal evaluation of chronic relapsing illness reveals evidence of neurodegenerative tissue loss. There is some evidence-albeit preliminary and somewhat controversial-that antipsychotic medications can obviate and/or ameliorate these changes. This chapter will describe the neurobiology of schizophrenia with a focus on the timing, evolution, and putative neurobiological correlates of treatment-refractoriness in schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=84956827005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956827005&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-45257-4_2

DO - 10.1007/978-3-642-45257-4_2

M3 - Chapter

SN - 9783642452567

SP - 21

EP - 30

BT - Treatment-Refractory Schizophrenia

PB - Springer Berlin Heidelberg

ER -